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osting by EAbstract Abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana) is an intravenous
agent that had been approved for treatment of acute coronary syndrome undergoing coronary
interventions. It is a chimeric monoclonal antibody fragment that binds to the glycoprotein IIb/IIIa
receptor with a potential for the development of an immune response to variable portions within the
antigen binding site following its administration.
We describe a 58-year-old man who developed sudden headache, short of breath, choking and
restlessness after receiving Abciximab for coronary intervention. Discontinuation of abciximab
and administration of intravenous ﬂuids, steroid and antihistamines led to improvement of his
symptoms gradually.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Abciximab (ReoPro, manufactured by Centocor and distrib-
uted by Eli Lilly and Company, Indianapolis, Indiana) is an
intravenous agent that had been approved by the Food and
Drug Administration for treatment of acute coronary syn-
drome undergoing coronary interventions. It is a chimeric6 506276861; fax: +966 1 477
c.med.sa, almoghairi@gmail.
y. Production and hosting by
Saud University.
lseviermonoclonal antibody fragment (c7E3 Fab) that binds to the
glycoprotein IIb/IIIa receptor with a potential for the develop-
ment of an immune response to variable portions within the
antigen binding site following its administration. Anti-abcix-
imab responses are predominantly of the IgG isotope and chi-
meric antibodies, which have been thought to reduce the risk
of hypersensitivity reactions, hence the anaphylaxis is extremely
rare (Tcheng et al., 2001). However, there are some reported
cases with variable allergic reactions to abciximab with variable
severity (Guzzo and Nichols, 1999; Iakovou et al., 2001; Pha-
rand et al., 2002; Hawkins et al., 2003). The human antichimeric
antibodies (HACAs) to abciximab occur in 6–7% of patients
after the ﬁrst exposure (The EPIC investigators, 1994). The
re-administration of abciximab can be accomplished without
severe allergic responses (Dery et al., 2004).
The previous report of an immunohistological study after
an intra-dermal test revealed T-cell mediated reaction (Moner-
et-Vautrin et al., 2002).
We describe a patient who developed an immediate reaction
to abciximab and atypical symptoms compared with previous
reports.
Table 1 The patient score based on Naranjo Algorith.
Question Yes No Do not
know
Score
1. Are there previous conclusive reports on this reaction?  0
2. Did the adverse event appear after the suspected drug was administered?  +2
3. Did the adverse reaction improve when the drug was discontinued or a speciﬁc
antagonist was administered?
 +1
4. Did the adverse reaction reappear when the drug was readministered?  0
5. Are there alternative causes (other than the drug) that could on their own have
caused the reaction?
 +2
6. Did the reaction reappear when a placebo was given?  +1
7. Was the drug detected in the blood (or other ﬂuids) in concentrations known to
be toxic?
 0
8. Was the reaction more severe when the dose was increased, or less severe when
the dose was decreased?
 0
9. Did the patient have a similar reaction to the same or similar drugs in any
previous exposure?
 0
10. Was the adverse event conﬁrmed by any objective evidence?  0
Modiﬁed from Naranjo et al. (1981).
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The suffering 58-year-old man is diabetic, hypertensive and
dyslipidemic. He has no prior drug allergy, and underwent cor-
onary bypass surgery four years earlier. He presented with
unstable angina. His coronary angiography revealed patent
left anterior descending and obtuse marginal artery grafts,
with occluded venous graft to occluded native right coronary
artery. The decision was made to perform a percutaneous cor-
onary intervention to the native right coronary artery, and the
lesion was crossed with an intervention wire with weight-ad-
justed unfractionated heparin and abciximab (glycoprotein
IIb/IIIa inhibitor) bolus ahead of the procedure. The proximal
part was pre-dilated and stented successfully with good distal
blood ﬂow. A signiﬁcant distal stenosis was postponed because
the patient suddenly became restless, short of breath, with se-
vere headache, throat, neck, and shoulder pains, and he was
choking. His lung examination showed scattered rhonchi while
his blood pressure was 146/95 mmHg. There was no focal neu-
rological deﬁcit.
We quit the procedure and discontinued the abciximab
infusion, and intravenous steroids and antihistamines were gi-
ven and an urgent Brain Computed tomography was per-
formed to rule out intracranial hemorrhage. The patient was
stabilized and the CT brain reported normal. All other labora-
tory results were normal, including platelets count.
The next day he was discharged home. Four weeks later he
was admitted to ﬁx the distal RCA disease and we considered
him allergic to abciximab, and the procedure was completed
uneventfully using the same contrast and unfractionated hepa-
rin without any speciﬁc premedication, and next day he was
discharged home.3. Discussion
There are some reported cases with variable allergic reactions
to abciximab with variable severity (Guzzo and Nichols,
1999; Iakovou et al., 2001; Pharand et al., 2002; Hawkins
et al., 2003). The re-administration of abciximab can beaccomplished without severe allergic responses (Dery et al.,
2004). The previous report of an immunohistological study
after an intra-dermal test revealed a T-cell mediated reaction
(Moneret-Vautrin et al., 2002).
Herein we describe a patient who developed severe head-
ache, shoulders pain, choking and shortness of breath shortly
after administration of abciximab with elevated blood pressure
and absence of neurological localizing signs which had not
been described with abciximab before. After discontinuation
of the drug and initial resuscitative measures established and
exclusion of intracranial hemorrhage by immediate brain com-
puted tomography the drug allergy became the most likely
cause. This is conﬁrmed with readmission later to complete
revascularization without any events in absence of abciximab.
We applied The Naranjo Algorithm for evaluating the prob-
ability of an adverse drug reaction, and we found that this case
falls in range of 5–8 score indicating a probable causal relation,
as shown in the Table 1 below (Naranjo et al., 1981).
The new ﬁnding in this case is the immediate reaction to
abciximab and atypical symptoms compared with previous re-
ports where they report angioedema, hypotension and throm-
bocytopenia, which our patient does not have (Curtis et al.,
2004).
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